Insomnia - Wake-Up Call for a Sleepy Market

Questions: Discounts, Updates etc.

Price: $1,900.00

Publication Date: 2004-07-13

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Approximately 50% of the population experience symptoms of insomnia on a regular basis. However, only a fraction of patients are diagnosed, with even fewer receiving prescribed pharmacological therapy. Currently Sanofi's Ambien (zolpidem) is the market leader across the seven major markets, with revenues of $1.7 billion in 2003.


Scope

  • Overview of the epidemiology of insomnia in order to assess the untapped patient potential offered by this disorder
  • Analysis of why the US insomnia market has flourished, and of how similar success can be achieved in Europe in the future
  • Evaluation of the current market leaders and primary contenders for entrance in to the market
  • Assessment of product positioning and life-cycle management strategies of branded and pipeline manufacturers


    • Report Highlights
    Datamonitor estimates that approximately 67 million insomnia patients will receive prescribed drug therapy in 2004 across the seven major markets, although the potential patient population is considerably higher at 238 million across the seven major markets.

    Ambien is currently the market-leading insomnia drug, with a 94% share of the branded insomnia market. However, the drug will face increasing competition with the launch of generic zolpidem and numerous novel drugs.

    Sepracor's Estorra and Neurocrine/Pfizer's indiplon are expected to reach market during 2005, and will drive the growth of the insomnia market, both reaching blockbuster status within the forecast period.


    Reasons to Purchase

  • Analyze the commercial viability of the insomnia market, based on estimated patient numbers, historical and forecast sales data
  • Develop an understanding of key unmet needs of the insomnia market, market entry and consolidation strategies a current and future players
  • Identify and assess novel R&D compounds in the insomnia pipeline

    • Table of Contents

    Other users found this report page using the following search terms: insomnia sleep disorders insomnia market zimovane patent indiplon pipeline generic expiry zolpidem population

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.